Braveheart Bio BRVE
$20.39 +$1.12 (+5.81%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $20.39 0.00%
Open$19.29
Prev close$19.27
Day range$18.83 – $21.16
Volume866.7K
Market cap$1.83B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$30.15M+49.1% YoY
Net profit-$26.50M+55.2% YoY
Diluted EPS-$0.51+63.1% YoY
Free cash flow-$24.37M+27.2% YoY
Operating cash flow-$24.37M
Revenue, last 7 quarters
Net profit, last 7 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Return on equity-13.2%
Return on assets-12.8%
Return on invested capital-14.4%
Current ratio21.57
Liabilities / assets3.3%
Cash & investments$349.27M
Total debt$100,000.00
Net cash (debt)$349.17M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Non-Operating Interest Income (Expense) | $3.71M | $889,000.00 | $771,000.00 | $696,000.00 | $527,000.00 |
| Operating Expense | $30.15M | $15.88M | $15.05M | $66.75M | $6.98M |
| Selling and Admin Expenses | $12.61M | $4.76M | $4.14M | $3.02M | $2.48M |
| -General & Admin Expense | $12.61M | $4.76M | $4.14M | $3.02M | $2.48M |
| Research & Development | $17.54M | $11.13M | $10.91M | $63.73M | $4.50M |
| Operating Profit | -$30.15M | -$15.88M | -$15.05M | -$66.75M | -$6.98M |
| Net Profit | -$26.50M | -$14.99M | -$14.28M | -$66.05M | -$6.45M |
| Non-Operating Interest Income | $3.71M | $889,000.00 | $771,000.00 | $696,000.00 | $527,000.00 |
| Other Income (Expense) | -$58,000.00 | $5,000.00 | -$2,000.00 | $1,000.00 | – |
| Other Non-Operating Income (Expenses) | -$58,000.00 | $5,000.00 | -$2,000.00 | $1,000.00 | – |
| Pretax Profit | -$26.50M | -$14.99M | -$14.28M | -$66.05M | -$6.45M |
| Profit from Continuing Operations | -$26.50M | -$14.99M | -$14.28M | -$66.05M | -$6.45M |
| Net Income to Parent Company | -$26.50M | -$14.99M | -$14.28M | -$66.05M | -$6.45M |
| Net Income to Common Stockholders | -$26.50M | -$18.60M | -$14.28M | -$66.05M | -$6.45M |
| Basic EPS | -$0.51 | -$0.30 | -$0.33 | -$5.32 | -$0.10 |
| Diluted EPS | -$0.51 | -$0.30 | -$0.33 | -$5.32 | -$0.10 |
| Preferred Stock Dividends | – | $3.62M | – | – | – |
| Special Income (Charges) | – | $0.00 | $0.00 | -$62.24M | – |
| -Less:Other Special Charges | – | – | – | $62.24M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $514.45M | $126.96M | $81.88M | $89.35M | $89.35M |
| Total Current Assets | $359.57M | $123.45M | $81.07M | $89.28M | $89.28M |
| Cash and Cash Equivalents & Short-Term Investments | $349.27M | $122.83M | $80.58M | $89.16M | $89.16M |
| -Cash and Cash Equivalents | $121.29M | $122.83M | $80.58M | $89.16M | $89.16M |
| -Short Term Investments | $227.98M | – | – | – | – |
| Other Current Assets | $10.30M | $614,000.00 | $496,000.00 | $119,000.00 | $119,000.00 |
| Total Non-Current Assets | $154.88M | $3.51M | $806,000.00 | $70,000.00 | $70,000.00 |
| Net PPE | $530,000.00 | $630,000.00 | $736,000.00 | – | – |
| Additional Paid-In Capital | $620.71M | $0.00 | $1.94M | $179,000.00 | $179,000.00 |
| -Preferred Stock | $0.00 | $213.52M | $149.89M | $149.89M | $149.89M |
| Retained Earnings | -$122.40M | -$95.91M | -$80.33M | -$66.05M | -$66.05M |
| Gains/Losses Not Affecting Retained Earnings | -$718,000.00 | – | – | – | – |
| Other Non-Current Liabilities | $75,000.00 | $86,000.00 | $89,000.00 | $91,000.00 | $91,000.00 |
| -Long Term Capital Lease Obligation | $100,000.00 | $198,000.00 | $294,000.00 | – | – |
| Long Term Debt and Capital Lease Obligation | $100,000.00 | $198,000.00 | $294,000.00 | – | – |
| Total Non-Current Liabilities | $175,000.00 | $284,000.00 | $383,000.00 | $91,000.00 | $91,000.00 |
| -Current Capital Lease Obligation | $415,000.00 | $377,000.00 | $373,000.00 | – | – |
| Current Accrued Expenses | $5.52M | $4.47M | $1.19M | $3.87M | $3.87M |
| -Accounts Payable | $1.98M | $2.67M | $7.74M | $1.06M | $1.06M |
| Total Equity | $497.60M | $117.61M | $71.49M | $84.02M | $84.02M |
| Stockholders' Equity | $497.60M | $117.61M | $71.49M | $84.02M | $84.02M |
| Capital Stock | $8,000.00 | $213.52M | $149.89M | $149.89M | $149.89M |
| -Common Stock | $8,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| Short-Term Debt and Capital Lease Obligation | $415,000.00 | $377,000.00 | $373,000.00 | – | – |
| Total Liabilities | $16.85M | $9.34M | $10.39M | $5.33M | $5.33M |
| Payables | $1.98M | $2.67M | $7.74M | $1.06M | $1.06M |
| -Gross PPE | $530,000.00 | $630,000.00 | $736,000.00 | – | – |
| Other Non-Current Assets | $98,000.00 | $70,000.00 | $70,000.00 | $70,000.00 | $70,000.00 |
| Total Current Liabilities | $16.67M | $9.06M | $10.00M | $5.24M | $5.24M |
| -Available for Sale Securities | $154.25M | – | – | – | – |
| Investments and Advances | $154.25M | – | – | – | – |
| Convertible preferred securities | – | $213.52M | $149.89M | $149.89M | – |
| Non-Current Deferred Assets | – | $2.81M | – | – | – |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$24.37M | -$16.95M | -$5.19M | -$2.01M | -$1.27M |
| Net cash flow from continuing operations | -$24.37M | -$16.95M | -$5.19M | -$2.01M | -$1.27M |
| Net Income from Continuing Operations | -$26.50M | -$14.99M | -$14.28M | -$66.05M | -$6.45M |
| Depreciation & Depletion & Amortization | $3,000.00 | $3,000.00 | $2,000.00 | – | – |
| Change in Working Capital | -$6.32M | -$3.05M | $7.33M | $1.62M | $1.98M |
| -Change in Prepaid Assets | -$9.69M | -$120,000.00 | -$342,000.00 | -$119,000.00 | -$108,000.00 |
| -Change in Payables and Accrued Expense | $3.33M | -$2.93M | $7.78M | $1.81M | $2.16M |
| -Change In Other Working Capital | $70,000.00 | $0.00 | -$105,000.00 | – | – |
| Net cash flow from investing | -$382.45M | $8,000.00 | -$3.04M | -$33.57M | -$835,000.00 |
| Net Common Stock Issuance | $0.00 | – | – | $95,000.00 | $89,000.00 |
| Ending Cash Balance | $121.29M | $122.83M | $80.58M | $89.16M | $89.16M |
| Net Other Financing Charges | -$3.79M | -$399,000.00 | -$363,000.00 | – | – |
| Net Preferred Stock Issuance | -$15,000.00 | – | – | $124.65M | $23.65M |
| Net Cash Flow from Continuing Financing Activities | $405.28M | $59.20M | -$363,000.00 | $124.74M | $23.74M |
| Financing Cash Flow | $405.28M | $59.20M | -$363,000.00 | $124.74M | $23.74M |
| Net Intangibles Purchase and Sale | $0.00 | $0.00 | -$3.00M | -$33.57M | -$835,000.00 |
| Beginning Cash Balance | $122.83M | $80.58M | $89.16M | $0.00 | $67.53M |
| Net PPE Purchase and Sale | $0.00 | $8,000.00 | -$36,000.00 | – | – |
| Free Cash Flow | -$24.37M | -$16.94M | -$8.22M | -$35.58M | -$2.11M |
| Net Cash Flow from Continuing Investing Activities | -$382.45M | $8,000.00 | -$3.04M | -$33.57M | -$835,000.00 |
| Net Change in Cash | -$1.54M | $42.26M | -$8.59M | $89.16M | $21.63M |
| -Change in Other Current Assets | – | – | – | -$70,000.00 | -$70,000.00 |
| Other Non-Cash Items | – | – | – | $62.24M | $3.03M |
No comments yet — be the first to weigh in on BRVE.
Sign in to join the discussion.